FRTX 10
Alternative Names: BBI-10; FRTX-10Latest Information Update: 25 Sep 2023
At a glance
- Originator Carna Biosciences
- Developer Fresh Tracks Therapeutics
- Class Anti-inflammatories; Hepatoprotectants; Small molecules
- Mechanism of Action MPYS protein inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Discontinued Dermatomyositis; Inborn genetic disorders; Inflammation; Non-alcoholic steatohepatitis; Systemic lupus erythematosus